Cataract Articles & Analysis
42 news found
Dr Mansouri is a medical and surgical eye specialist, sub-specializing in glaucoma and cataract. Currently a Consultant Ophthalmologist at the Glaucoma Center, Swiss Visio, Clinique de Montchoisi, and an Adjoint Professor at the Department of Ophthalmology, University of Colorado School of Medicine (Denver, USA), he is an expert in the fields of minimally invasive glaucoma ...
“We look forward to the impact this technology will offer patients suffering from cataracts and presbyopia, two of the largest segments of the ophthalmology market.” Nearly 67 million people worldwide are visually impaired due to cataracts, which can lead to blindness if untreated.1 Atia Vision’s modular intraocular lens technology aims to ...
The company Swiss Advanced Vision (SAV-IOL SA) announced today the launch of LUCIDIS and EDEN, two new intraocular lenses (IOLs) for the cataract surgery, both using the Instant Focus EDOF patented technology. ...
The final study results demonstrated that canaloplasty and trabeculotomy performed as an implant-free minimally invasive glaucoma surgery (MIGS) using the OMNI® Surgical System in conjunction with cataract surgery significantly reduced unmedicated mean diurnal intraocular pressure (IOP), medication use and daily fluctuations in IOP in patients with open-angle glaucoma (OAG). ...
First, the physician and medical staff are protected from radiation exposure during the procedure; daily exposure to X-rays by physicians that use manual coronary angioplasty has been linked to harmful effects such as cancer and cataracts. Second, physicians using the R-One robotic system do not need to wear heavy lead protective gear; preventing musculoskeletal conditions caused ...
ByRobocath
We will build on this momentum in 2022 and continue to execute our three strategic initiatives: (1) converting more Combination Cataract MIGS surgeons to OMNI, (2) developing the $5 billion U.S. Standalone MIGS segment, and (3) pioneering optimal access to effective MGD patient care. ...
The TRIDENT study is a prospective, randomized, multicenter, comparative trial evaluating the safety and effectiveness outcomes, including IOP reduction, for pseudophakic eyes (eyes which had previously undergone cataract surgery) in three study arms: (1) canaloplasty alone using the OMNI Surgical System, (2) sequential canaloplasty followed by trabeculotomy using the OMNI ...
The second product is a Levofloxacin SR Ocular Implant, an antibiotic-based ocular implant, being developed as a treatment to reduce the risk of infection after cataract surgery. PolyActiva is based in Melbourne, Australia, and has secured venture capital funding from Brandon Capital’s Medical Research Commercialisation Fund (MRCF) and Yuuwa Capital. ...
” While MIGS first entered the market as an implant-based procedure performed only at the time of cataract surgery, the OMNI® Surgical System*, an implant-free MIGS, is now cleared by the FDA more broadly for use not only in combination with cataract surgery but also as a standalone procedure to lower IOP in adult patients with primary open-angle ...
Currently in the U.S., MIGS implants are approved only in conjunction with cataract surgery, not as a standalone procedure. The FRONTIER trial will evaluate the effectiveness of the Hydrus Microstent in patients who have already had cataract surgery, making the study a vital addition to the growing body of evidence on the Hydrus Microstent. ...
Osmolarity testing enables clinicians to detect visually significant ocular surface disease, and is considered an essential test by the American Society of Cataract and Refractive Surgery. Abnormal osmolarity can adversely impact accuracy of refractive measurements and the TearLab osmolarity test empowers clinicians to accurately diagnose dry eye disease. ...
BySOFIE
Nir Dotan was previously Vice President of Human Resources at Hanita Lenses, a medical device manufacturer and provider of intraocular lens solutions for cataract surgery, and previously served in roles handling recruitment and marketing. ...
“Post hoc analysis of the GEMINI data suggests that ab-interno canaloplasty plus goniotomy using the OMNI Surgical System combined with cataract surgery has the potential to control IOP fluctuations, a known risk factor for the progression of glaucoma,” said Mark F. ...
Combining Hydrus with cataract surgery is an opportunity to treat patients early in their disease state. ...
Bio-Tissue, Inc., a TissueTech company and pioneer in the clinical application of human birth tissue allografts to promote regenerative healing for ocular surface disease and disorders, announced today that it has entered into a Vendor Agreement with EyePro Group Purchasing Organization (GPO), LLC. As such, GPO members can now take advantage of membership purchasing volume discounts to access ...
Approved by the FDA in August 2018 for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma (POAG), the Hydrus Microstent is the most rigorously researched and thoroughly studied MIGS devices, with more than 4,000 cases treated globally in controlled clinical studies and ...
The post-cataract surgery lens may be able to deliver a combination corticosteroid, NSAID and antibiotic treatment from a single lens. Ophthalmologists will apply the lens after the cataract surgery and patients can wear the lens for one week or longer to deliver the medication, instead of needing to use multiple eye drops every day. ...
Ken Mandell, Founder and CEO of LayerBio, presented an update on the development of its novel OcuRing-K ketorolac implant for treatment of postoperative pain and inflammation with cataract surgery. To see video, please click ...
One of the most important and noteworthy findings of this study is that, of the patients who went on to receive subsequent invasive surgery in the cataract-surgery-only arm, the majority were those who had what we would consider mild glaucoma at baseline. ...
And for some, that delayed care threatened to leave patients in the dark. Visits for cataracts plummeted 97% and encounters for glaucoma, which can cause blindness, were down 88%. ...